professional naming

for the healthcare and pharmaceutical industry

The U.S. Food and Drug Administration

The Food and Drug Administration (FDA) in the US and the European Medicines Agency (EMA) in Europe must approve pharmaceutical compounds and biologics prior to public consumption. The brand names for these drugs must also be authorized and approved.

 

The primary function of the FDA naming process is to minimize or eliminate the risk of medication errors that result from the branding or naming of a pharmaceutical product. Its secondary function is to make sure that approved names don’t communicate anything false or misleading to consumers who may be taking the drug. This is from both a safety perspective, as well as an expectation perspective on the part of the patient. 

Maximizing a successful outcome

The most significant steps to take involve testing and examining the name before applying for trademark protection or submitting the name to the FDA or any global regulatory authority. One way to legally minimise the risk of rejection and accelerate the success of the process is to understand how the FDA evaluates names and what factors they consider. Look at the drug candidate and the FDA process and be aware of the other products and drug treatments available, understand the generic nature of the ingredients that are part of the actives as well as the excipients, and make a first level cut at what should move forward in the process.

Testing

The next step is to test the name candidates for similarity to other brand names on the market and consider the proposed names from the oral or spoken perspective. Is it going to sound too much like something else when called out by a medical professional, patient or even pharmacist? Always consider whether a doctor’s written prescription is going to look too similar to something else. Studies have shown that when a physician writes a prescription the first couple letters of the drug name are clearer than the last couple.

 

So, if you have two drugs that begin with the same letter string, there may be an increased likelihood for confusion at the point of dispensing, and an increased risk of a medical mistake.

It is important to test candidate names through interviews, focus groups or online testing to end-users and professionals.

If the new drug is expected to be a blockbuster, be sure to invest in testing the name with relevant constituencies before you even walk through the door at the FDA. This may help speed up the FDA approval and will help to avoid potential rebranding situations later on in the process.

We usually recommend to register a number of names and then decide which 2 or 3 will be moved forward in the FDA process, to avoid that the FDA has approved your name only to learn that someone else was is already using the same name or a confusingly similar one for pharmaceuticals or in a related area that doesn’t require regulatory approval. 

Over The Counter drugs

For OTC drugs there are more issues to contend with because the risk of consumer confusion is greater as a result of the way that OTC drugs are presented through advertising, packaging, and point of sale merchandising. There are a number of things that are done to distinguish one brand from the next, including the core branding elements, which include the name itself and package presentation in terms of size, colour and layout. 

Nomenclature

Drugs always have three names, the chemical name, the nonproprietary name (every company can use it), and the proprietary name owned by one company.

Nurofen for instance is the brand name for isobutylphenylpropanoic acid, a non-steroidal anti-inflammatory drug (NSAID) used for relieving pain, helping with fever and reducing inflammation, called by its nickname ibuprofen and owned by Reckitt Benckiser.

 

Ibuprofen is sold under many other proprietary or brand names by different companies, of which the brands Advil, Anadin, Brufen and Motrin are the most well known.

 

Other proprietary names of ibuprofen in the market are: Actron, Adex, Arinac, Advifen, Aktren, Alaxan, Alges-X, Algifor, Algoflex, Algofren, Alindrin, Alivium, Arthrofen, Artofen, Betagesic, Betaprofen, Bonifen, Bugesic, Buplex, Burana, Buprofil, Caldolor, Calprofen, Combiflam, Dalsy, Dismenol, Diverin, Dolgit, Dolofort, Doloraz, Dolormin, Dolo-Spedifen, Dorival, Easofen, Ebufac, EmuProfen, Espidifen, Eve, Fenbid, Fenpaed, Finalflex, Galprofen, Ibu, Ibugel, Ibugesic, IbuHexal, Ibuleve, Ibum, Ibumax, Ibumetin, Ibumidol, Ibupain, Ibuprofene, Ibuprom, Ibuprox, Ibuprosyn, Nuprin and many others.     

About Pharmanaming.com and GNN

The Global Naming Network (GNN), headquartered in Geneva, is the world's largest network of independent naming and brand identity agencies.

 

With around 240 cooperating naming and branding specialists in 16  countries, from Beijing to New York and from Seoul to Paris, GNN works for clients ranging from large multinationals to small startups all over the world.

Pharmaceutical projects are coordinated from the GNN office in Amsterdam by the pharma naming specialists of Globrands.

The www.pharmanaming.com website is dedicated to our expertise and work for the health & pharma industry.

 

Please contact us for more information.

20

offices in 16 countries

240

creatives, strategists & consultants

GNN offices

China                     South Korea

France                   Italy
Germany               Japan

Netherlands          UK

India                      Singapore

Spain                     Canada

Switzerland          Russia

USA                       Dubai

5000

projects successfully executed

Pages

home                           name to brand

health & pharma        people

regulatory                   test & submit

India                             FDA

work                             blog

clients                          contact

20000

linguistic professionals worldwide

Globrands the name behind the brands

© 2020 by Globrands consultancy group

Herengracht 122, 1015 BT Amsterdam, the Netherlands

call +31206238555 or mail to pharma@globrands.com  

 

  • White LinkedIn Icon